Humacyte (HUMA) Stock
What Humacyte's price implies, from its SEC filings.
Key numbers
- P/E (forward)
- -1.84x
- Revenue growth
- +159.3%
- Operating margin
- -5,240.8%
- Debt / equity
- 1.16x
What Humacyte's price implies
Humacyte's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Revenue and free cash flow
Fiscal years, from Humacyte's 10-K filings.
Humacyte revenue and free cash flow
FY2020–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $2M |
| Net income | -$26M | -$12M | -$111M | -$149M | -$41M |
| Free cash flow | -$81M | -$72M | -$76M | -$100M | -$106M |
| EPS (diluted) | -$0.66 | -$0.12 | -$1.07 | -$1.26 | -$0.26 |
| Operating margin | — | — | — | — | -5,306.0% |
Superinvestors who own HUMA
From each investor's latest 13F filing (what a 13F shows). All 7 holders
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Tony Yoseloff Davidson Kempner Capital Management | New position | $4M | 0.10% | Q2 2026 |
| Cliff Asness AQR Capital Management | Added | $2M | 0.00% | Q2 2026 |
| Didric Cederholm Lion Point Capital | Held | $507,260 | 2.4% | Q2 2026 |
| Paul Marshall Marshall Wace | New position | $141,829 | 0.0% | Q2 2026 |
| Steve Cohen Point72 Asset Management | New position | $41,929 | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments | Trimmed | $23,059 | 0.0% | Q2 2026 |
| Paul Tudor Jones Tudor Investment Corp | Held | $9,599 | 0.0% | Q2 2026 |
Humacyte insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you). Every purchase
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Anthony Jones Keith Director | 10,000 | $0.56 | $5,620 |
| Aug 20, 2026 | Anthony Jones Keith Director | 10,000 | $0.69 | $6,930 |
| Aug 17, 2026 | Anthony Jones Keith Director | 30,000 | $0.59 | $17,820 |
| May 19, 2026 | Sebelius Kathleen Director | 56,818 | $0.88 | $50,000 |
| May 18, 2026 | T. Constantino Michael Director | 11,000 | $0.89 | $9,840 |
Fundamental grade
Five factors scored 1 to 9 from HUMA's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How Humacyte compares
Humacyte's revenue growth is higher than 92% of Healthcare companies and 97% of the 3,491 companies with a revenue growth figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Revenue growth | 92% | 97% |
| Operating margin | 4% | 1% |
| ROE | 2% | 1% |
Questions about Humacyte
Are Humacyte insiders buying the stock?
5 open-market insider purchases of HUMA in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Humacyte?
7 of the superinvestors Investingly tracks hold HUMA in their latest 13F, including Tony Yoseloff, Cliff Asness, Didric Cederholm.
Companies like Humacyte
Nkarta, Inc. (NKTX)$124MZentalis Pharmaceuticals, Inc. (ZNTL)$123MMolecular Partners AG (MOLN)$121MSpruce Biosciences, Inc. (SPRB)$128MMinerva Neurosciences, Inc. (NERV)$121MCoherus Oncology, Inc. (CHRS)$119MArmata Pharmaceuticals Inc (ARMP)$130MAdagene Inc (ADAG)$118MenGene Holdings Inc. Common Stock (ENGN)$117M All Healthcare stocks→Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.